{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:46:02Z","timestamp":1793727962305,"version":"4.6.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Autologous hematopoietic stem-cell transplant(ASCT) following high-dose chemotherapy is an established treatment for selected pediatric solid tumors. However, data from low- and middle-income countries(LMICs) remain scarce, where outcomes may be influenced by limited supportive care infrastructure and higher infection risks. Most available reports focus primarily on neuroblastoma, with little evidence for other solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included children, adolescents, and young adults (CAYA,0\u201325 years) with solid tumors treated at a tertiary-care center in India, aiming to assess survival outcomes, engraftment kinetics, and toxicities. Data were collected from patient files and electronic databases for those who underwent ASCT between January 2008 and June 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 92 patients, median age was 6y (IQR,4-16) with 69.6% males. Diagnoses included: high-risk neuroblastoma(HRNB,52.2%), relapsed\/refractory Ewing sarcoma(EWS,22.8%), relapsed\/refractory germ-cell tumors(GCT,15.2%), retinoblastoma(RB,5.4%), and soft-tissue sarcoma (STS,4.4%). Forty-three (46.8%) underwent ASCT in relapse\/refractory setting, while 49(53.2%) had upfront ASCT. Median CD34+cell dose was 5.7(IQR,3.5-6.9) million\/kg, with a median cryopreservation duration of 16(IQR,8-49) days. Median time to neutrophil-engraftment was 11(IQR,9-12) days. The 3-year OS of the entire cohort was 50.6% (95%CI: 36.8-62.9), and EFS was 35.9% (95%CI: 23.6-48.3). Three-year OS for HRNB, relapsed\/refractory-EWS, relapsed\/refractory-GCT, STS and RB were 48.5%(95%CI: 29.2-65.3), 43.8% (95%CI: 17.8-67.4), 56.3%(95%CI: 20.9-80.9), 66.7% (95%CI: 5.4-94.5), and 50.0%(95%CI: 6.0-91.0), respectively. For HRNB and EWS, BuMel-140 had better OS than CEM-200 [HR\u00a0=\u00a00.15,95%CI:0.04-0.7,p=0.005].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ASCT yields acceptable outcomes for selected high-risk or relapsed\/refractory pediatric solid tumors in LMICs, with outcomes in GCT comparable to global standards, based on experience from a high-volume transplant center.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1796956","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:28:03Z","timestamp":1781584083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Autologous stem cell transplantation for pediatric solid tumors in a resource-limited setting: a single-center experience of 15 years"],"prefix":"10.3389","volume":"16","author":[{"given":"Debabrata","family":"Mohapatra","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surender K.","family":"Sharawat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Agarwala","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101679","article-title":"Childhood cancer in India","volume":"71","author":"Ganguly","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102705","article-title":"Rurality and pediatric cancer survival in the United States: An analysis of SEER data from 2000 to 2021","volume":"94","author":"Hymel","year":"2025","journal-title":"Cancer Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_201189","article-title":"Management of refractory germ cell cancer","volume":"38","author":"Lorch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children\u2019s Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2516","article-title":"High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008","volume":"36","author":"Whelan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/jco.2011.29.18_suppl.2","article-title":"Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1\/SIOPEN trial","volume":"29","author":"Ladenstein","year":"2011","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-50026-3_13","article-title":"Engraftment, graft failure, and rejection","volume-title":"The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT","author":"Hutt","year":"2018"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30680","article-title":"Cost-effectiveness analysis of dinutuximab \u03b2 for the treatment of high-risk neuroblastoma in China","volume":"70","author":"Shen","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1186\/s12885-019-6407-5","article-title":"Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28273","article-title":"Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations","volume":"67","author":"Jain","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.31547\/bct-2023-016","article-title":"Autologous hematopoietic stem cell transplant at a tertiary care centre in India: achieving comparable outcomes with adaptations","volume":"7","author":"Gupta","year":"2024","journal-title":"Blood Cell Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2025.104067","article-title":"Successful of autologous hematopoietic stem cell mobilization with plerixafor combined with G-CSF in pediatric neuroblastoma patients, a single center experience","volume":"64","author":"Jafari","year":"2025","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"10536","DOI":"10.1200\/JCO.2020.38.15_suppl.10536","article-title":"Risk factors in the HR-NBL-1\/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy","volume":"38","author":"Ladenstein","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i8.629","article-title":"Management of neuroblastoma in limited-resource settings","volume":"11","author":"van Heerden","year":"2020","journal-title":"World J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/08880018.2020.1850955","article-title":"Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta","volume":"38","author":"Jain","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70069-X","article-title":"High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial","volume":"9","author":"Pearson","year":"2008","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34233","article-title":"Immunotherapy with anti-GD2 monoclonal antibody in infants with high-risk neuroblastoma","volume":"152","author":"Kushner","year":"2023","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01033-4","article-title":"Survival benefit of myeloablative therapy with autologous stem cell transplantation in high-risk neuroblastoma: A systematic literature review","volume":"19","author":"\u017bebrowska","year":"2024","journal-title":"Target Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg457","article-title":"Therapy and survival after recurrence of Ewing\u2019s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997","volume":"14","author":"Bacci","year":"2003","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102694","article-title":"High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party","volume":"124","author":"Ramamurthy","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008216.pub5","article-title":"Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas","volume":"4","author":"Peinemann","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2023.2187497","article-title":"High-dose chemotherapy with autologous stem cell transplantation for patients with extracranial germ cell tumors - experience of two Brazilian pediatric centers","volume":"40","author":"Villela","year":"2023","journal-title":"Pediatr Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S349035","article-title":"Clinical analysis of 16 distant metastatic retinoblastoma cases with event-free survival","volume":"14","author":"Li","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22825","article-title":"Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005","volume":"56","author":"Johnson","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1470-2045(22)00688-X","article-title":"Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis","volume":"24","author":"Bhatia","year":"2023","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz032","article-title":"Survival differences between males and females diagnosed with childhood cancer","volume":"3","author":"Williams","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children\u2019s Oncology Group Study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1247792","article-title":"Hospital survival following pediatric HSCT: changes in complications, ICU therapies and outcomes over 10 years","volume":"11","author":"Olson","year":"2023","journal-title":"Front Pediatr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.11.1931","article-title":"Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high\u2010dose chemotherapy followed by autologous stem\u2010cell transplantation","volume":"17","author":"Caglar","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071998","article-title":"Pediatric extracranial germ cell tumors: Review of clinics and perspectives in application of autologous stem cell transplantation","volume":"15","author":"Lew","year":"2023","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.025","article-title":"Length of stay and health care utilization among pediatric autologous hematopoietic cell transplantation recipients","volume":"27","author":"Davis","year":"2021","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Bufalo","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1796956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:28:07Z","timestamp":1781584087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1796956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1796956"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1796956","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1796956"}}